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Abstract
Background Metformin associated lactic acidosis (MALA) is a serious adverse event with a high mortality rate of 30–50%. 
Early recognition of MALA and timely starting treatment may reduce its morbidity and mortality. Objective The aim of this 
study was to explore clinical parameters to identify patients with MALA in patients with suspected sepsis induced lactic 
acidosis in the emergency department ED. Setting A retrospective single centre study was conducted at the Deventer Teach-
ing Hospital in the Netherlands. Method Patients with lactate concentration > 4.0 mmol/l admitted at the ED between 2010 
and 2017 with suspected sepsis or confirmed MALA and referred to the Intensive Care Unit were included. Baseline char-
acteristics (pH, lactate, creatinine and CRP) of MALA patients were compared with patients with suspected sepsis induced 
lactic acidosis. Creatinine and lactate concentration were selected as potential relevant parameters. Main outcome measure 
Sensitivity and specificity of the highest tertiles of the creatinine and the lactate concentrations separately, in combination, and 
both combined with metformin use, were calculated. Results Thirteen MALA and 90 suspected sepsis induced lactic acidosis 
patients were included. Lactate (14.7 vs 5.9 mmol/l, p < 0.01) and creatinine concentration (642 vs 174 μmol/l, p < 0.01) 
were significantly higher in the MALA group and arterial pH (7.04 vs 7.38, p < 0.01) and CRP (90 vs 185 mg/l, p < 0.01) 
were significantly lower. The combined parameters lactate ≥ 8.4 mmol/l, creatinine ≥ 256 μmol/l had a sensitivity of 85% and 
a specificity of 95% for identifying MALA in suspected sepsis induced lactic acidosis patients in the ED. When combined 
with metformin use the specificity increased to 99%. Conclusion When managing lactic acidosis in the ED the diagnosis 
MALA should be considered in patients with a creatinine concentration ≥ 256 μmol/l and lactate concentration ≥ 8.4 mmol/l.
Keywords Acidosis · Diagnosis · Lactic · Metformin · Renal insufficiency · Sepsis
Impacts on practice
• Early recognition of metformin associated lactic acidosis 
(MALA) and timely starting treatment may reduce its 
morbidity and mortality.
• Clinicians should be alert to MALA in the emergency 
department, especially in patients with a creatinine 
concentration ≥ 256  μmol/l and lactate concentra-
tion ≥ 8.4 mmol/l.
• Metformin serum concentration measurement should be 
available 24 h a day for diagnosis and management of 
MALA.
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Introduction
Metformin is recommended as the treatment of choice 
in patients with type 2 diabetes mellitus because it 
decreases cardiovascular morbidity and mortality [1, 2]. 
Metformin associated lactic acidosis (MALA) is a seri-
ous adverse event with a high mortality rate of 30–50% 
[3]. The reported incidence of MALA varies from 0 to 
138 per 100.000 patient years but this may be increas-
ing the coming years due to the increase in the number 
of type 2 diabetes mellitus patients and the use of met-
formin [3–5]. In addition, the guidelines for prescribing 
metformin have been changed: metformin use is not con-
traindicated any more in patients with more severe renal 
failure (eGFR < 45 ml/min) [6].
The clinical symptoms of MALA and sepsis are similar, 
but the treatment is different. As in sepsis, MALA is often 
accompanied by organ dysfunction e.g. renal failure and 
hypotension [7]. Furthermore, in sepsis, lactate concentra-
tions are frequently increased [8, 9]. Several studies sug-
gest that starting timely treatment of MALA might reduce 
MALA-related morbidity and mortality [5, 10–15]. Iden-
tifying MALA patients in an early stage may also avoid 
unnecessary expensive and high risk diagnostic tests as 
e.g. CT-abdomen at the ED. Information about metformin 
use is not always known or fast available on admission at 
the ED. Measuring metformin serum concentrations can 
be helpful in diagnosing MALA but this is not routinely 
available in most hospitals [16–18].
In the treatment of MALA, extracorporeal treatment 
(ECTR) may be necessary to remove metformin, clear lac-
tate and correct acid–base abnormalities [19]. The Extra-
corporeal Treatments in Poisoning Workgroup (EXTRIP) 
Group formulated recommendations for ECTR in the 
treatment of metformin poisoning [19, 20]. Clinical cri-
teria to identify sepsis and septic shock are described by 
Singer et al. [21]. The management of the septic patient is 
described in the Surviving Sepsis Campaign International 
Guidelines 2016 [8]. Lactate is the most common sero-
logic test used in the ED for risk stratification in suspected 
sepsis patients to optimize treatment but hyperlactatemia 
may be caused by conditions other than sepsis [8, 21, 22]. 
The differentiation between different origins of hyper-
lactatemia can be very difficult in clinical practice and 
there is a risk of misclassification [23]. In sepsis lactate is 
formed under hypoxic conditions and in MALA there is 
no evidence of a hypoxic condition [23]. The most widely 
accepted and established mechanism of hyperlactatemia 
and metabolic acidosis of metformin is partial inhibition of 
oxidative phosphorylation complex 1 of the mitochondrial 
electron transport chain. Another possible mechanism in 
which metformin may elevate plasma lactate levels is 
through inhibition of pyruvate carboxylase which results 
in both accelerated lactate production and reduced lactate 
metabolism [24, 25].
Aim of the study
Early recognition of MALA and timely starting treatment 
may reduce morbidity and mortality. Therefore, the aim of 
this study was to explore clinical parameters that could be 
used to identify MALA patients in patients with suspected 
sepsis induced lactic acidosis in the ED intended for use in 
further research.
Ethics approval
This study was performed after written consent of the Insti-
tutional Review Board and Board Director of the Deven-
ter Teaching Hospital. Due to the retrospective nature of 
the study in which patient data were used anonymously, no 
informed consent of patients was needed.
Methods
A retrospective single centre study was conducted at the 
Deventer Teaching Hospital in the Netherlands. Laboratory 
data were searched for patients admitted at the ED with lac-
tate levels > 4.0 mmol/l between January 2010 and Janu-
ary 2017. Patients with the diagnosis suspected sepsis or a 
confirmed diagnosis of MALA and who were admitted at 
the ICU were included. Patients who were not admitted at 
the ICU, who had a diagnosis other than suspected sepsis 
or MALA, who died within 24 h after admittance and all 
patients with an intentional overdose with metformin were 
excluded.
The following data were extracted from the medical 
records: age, gender, Acute Physiology and Chronic Health 
Evaluation II (APACHE II), treatment (supportive care or 
extracorporeal treatment ECTR), mortality and laboratory 
results on admission: serum concentrations of creatinine, 
lactate, C-reactive protein (CRP) and metformin and blood 
pH. The APACHE II score is a common ICU scoring system 
to classify disease state and to predict mortality risk and 
prognosis.
The diagnosis suspected sepsis was extracted from the 
medical records and was based on quick Sequential Organ 
Failure Assessment (qSOFA) and or systemic inflammatory 
response syndrome (SIRS) criteria.
The included patients were divided into 2 groups: 
MALA and suspected sepsis induced lactic acido-
sis. MALA was confirmed by a pH < 7.35 and lactate 
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concentration > 5.0 mmol/l and a metformin serum concen-
tration > 5 mg/l, simultaneously measured at admission [3]. 
In the Deventer Teaching Hospital the metformin assay is 
routinely available 24 h a day. Results are available for clini-
cal decisions within 4 h.
Baseline characteristics between groups were compared 
using the Mann–Whitney test because of non-normal distrib-
uted data. Based on clinical experience and previous studies, 
creatinine and lactate concentration were selected as poten-
tial diagnostic clinical parameters and were categorized into 
tertiles [4, 5, 7, 11–13, 15, 18, 26–29]. The sensitivity and 
specificity of the highest tertiles of these concentrations 
were calculated separately, in combination and both com-
bined with metformin use respectively. The sensitivity was 
calculated by dividing the number of MALA patients with 
the specified clinical parameter(s) by the total number of 
MALA patients. The specificity was calculated by dividing 
the number of patients without MALA not having the speci-
fied clinical parameter(s) by the total number of patients 
without MALA.
In all tests, a p-value < 0.05 was considered statistically 
significant. Data analysis was performed with SPSS version 
24.0.
Results
In total 103 patients were included: 13 MALA patients and 
90 suspected sepsis induced lactic acidosis patients. Patient 
characteristics of both groups are depicted in Table 1. There 
was no difference in age and APACHE II score between 
groups. The MALA group consisted of significantly more 
women compared to the suspected sepsis induced lactic aci-
dosis group (85% versus 40%). Lactate and creatinine con-
centration were significantly higher in the MALA group and 
arterial pH and CRP were significantly lower. The treatment 
modality ECTR was more frequently used and mortality was 
higher in the MALA group. 26% of the suspected sepsis 
induced lactic acidosis patients used metformin but did not 
comply with the definition of MALA. Four patients in the 
MALA group had positive urine cultures but none of them 
had positive blood cultures.
Lactate and creatinine concentration were selected as 
potential relevant clinical parameters.
Lactate concentration was categorized into tertiles 
resulting in the groups: ≤ 5.5  mmol/l, 5.6–8.3  mmol/l 
and ≥ 8.4  mmol/l. The creatinine concentration tertiles 
resulted in the groups: ≤ 142  μmol/l, 143–255  μmol/l 
and ≥ 256 μmol/l. A scatterplot in Fig. 1 shows the rela-
tionship between lactate and creatinine concentrations of all 
patients in relation to the highest tertiles.
Table 1  Patient characteristics
MALA metformin associated lactic acidosis, CRP C-reactive protein, APACHE Acute Physiology and 
Chronic Health Evaluation II, ECTR extracorporeal treatment
a Metformin serum concentration in metformin users is not measured or below 5 mg/l
b APACHE II scores and mortality prediction as percentage death rate:
0–4 ≅ 1–4%  15–19 ≅ 12–24%  30–34 ≅ 75%
5–9 ≅ 3–8%  20–24 ≅ 30–40%   > 34 ≅ 85%
10–14 ≅ 7–15%  25–29 ≅ 35–55%






N (%) 90 (87) 13 (13)
Age (years) (median, percentiles 25–75) 70 (64–80) 72 (63–81) 0.74
Gender male (%) 54 (60) 2 (15)  < 0.01
Creatinine (μmol/l) (median, percentiles 25–75) 174 (118–258) 642 (260–801)  < 0.01
Lactate (mmol/l) (median, percentiles 25–75) 5.9 (4.8–8.3) 14.7 (11.0–22.5)  < 0.01
pH (median, percentiles 25–75) 7.38 (7.28–7.43) 7.04 (6.83–7.18)  < 0.01
CRP (mg/l) (median, percentiles 25–75) 185 (90–305) 90 (34–145)  < 0.01
Metformin use (%) 23 (26) 13 (100)
Metformin (mg/l) (mean ± sd) a 27.5 ± 15.3
APACHE  IIb (median, percentiles 25–75) 26.5 (21.0–32.3) 26.0 (23.0–33.0) 0.53
ECTR yes (%) 9 (10) 10 (77)  < 0.01
Mortality (%) 19 (21) 6 (46) 0.049
1289International Journal of Clinical Pharmacy (2020) 42:1286–1292 
1 3
The sensitivity and specificity of the highest tertiles 
of lactate and creatinine concentration are depicted in 
Table  2. Sensitivity and specificity are presented in 
relation to lactate and creatinine concentration sepa-
rately, in combination and both in combination with 
metformin use. Among these, the combined parameters 
lactate ≥ 8.4 mmol/l, creatinine ≥ 256 μmol/l and met-
formin use showed the highest combination of sensitiv-
ity (85%) and specificity (99%) in identifying MALA 
patients from patients with suspected sepsis induced lac-
tic acidosis in the ED.
Fig. 1  Scatterplot of creatinine 
and lactate concentrations from 
the MALA and suspected sepsis 
induced lactic acidosis patients.
Dotted lines present the highest 
tertiles lactate and creatinine 
concentration.  
SSILA suspected sepsis induced 
lactic acidosis
Table 2  Sensitivity and specificity of parameters for identifying MALA patients in patients with suspected sepsis induced lactic acidosis
MALA metformin associated lactic acidosis
Clinical parameter MALA  
N = 13
Patients without 
MALA N = 90
Lactate ≥ 8.4 mmol/l (N) 13 21
Lactate < 8.4 mmol/l (N) 0 69
Sensitivity (%)/specificity (%) 100 76.6
Creatinine ≥ 256 μmol/l (N) 11 23
Creatinine < 256 μmol/l (N) 2 67
Sensitivity (%)/specificity (%) 84.6 74.4
Metformin use (yes) 13 23
Metformin use (no) 0 67
Sensitivity (%)/specificity (%) 100 74.4
Lactate ≥ 8.4 mmol/l and creatinine ≥ 256 μmol (N) 11 5
Lactate < 8.4 mmol/l and/or creatinine < 256 μmol (N) 2 85
Sensitivity (%)/specificity (%) 84.6 94.4
Lactate ≥ 8.4 mmol/l and creatinine ≥ 256 μmol and metformin use (yes) (N) 11 1
Lactate < 8.4 mmol/l and/or creatinine < 256 μmol and/or metformin use (no) (N) 2 89
Sensitivity (%)/specificity (%) 84.6 99.0
1290 International Journal of Clinical Pharmacy (2020) 42:1286–1292
1 3
Discussion
The aim of this study was to explore clinical parameters 
to identify MALA patients in patients with suspected sep-
sis induced lactic acidosis in the ED. This is important 
because early recognition of MALA may improve treat-
ment and reduce morbidity and mortality. The results 
show that the combined parameters lactate ≥ 8.4 mmol/l 
and creatinine ≥ 256 μmol/l have a sensitivity and speci-
ficity of 85% and 95% respectively for identifying MALA 
in suspected sepsis induced lactic acidosis in the ED. The 
specificity is increased to 99% when combining this with 
metformin use.
The MALA group in this study had more severe meta-
bolic acidosis (higher lactate and lower pH) and more severe 
renal dysfunction (higher creatinine concentration) com-
pared to the suspected sepsis induced lactic acidosis group. 
The clinical parameters (lactate, pH, creatinine, metformin 
serum concentration) of the MALA group in this study are in 
line with previous literature [4, 5, 7, 11–13, 15, 18, 26–29]. 
To our knowledge, this is the first study comparing MALA 
and suspected sepsis induced lactic acidosis patients. Three 
related studies were found [7, 10, 22]. Semely et al. [10] 
have shown that an early MALA diagnosis procedure in all 
patients with metformin admitted at the ED tends to decrease 
mortality, especially for serious MALA cases. Friesecke 
et al. [7] have compared MALA patients with patients with 
lactic acidosis of other origin (LAOO). They found, as in 
our study, a significantly higher lactate concentration and 
significantly lower blood pH in MALA patients. Green et al. 
[22] have shown in adult ED patients with suspected sepsis 
that metformin users had slightly higher lactate concentra-
tions and hyperlactatemia but this was not associated with a 
higher mortality risk.
If MALA was not considered as a cause of the hyper-
lactatemia in this study, 13% of the patients would have 
received sepsis treatment and adequate MALA treatment 
was possibly started too late or not at all leading to a higher 
mortality. The mortality in our MALA group of 46% is in 
accordance with results presented in previous literature, i.e. 
30–50% [5, 19]. In addition, the measured mean APACHE II 
scores of 26.5 matches the mortality in this study. APACHE 
II scores of 25–29 are associated with an approximated in-
hospital mortality of 35–55% [30]. However, the mortality 
in the sepsis group of 21% is, relatively low compared to 
literature and the measured APACHE II score of 26.0 [8, 
30]. Not all our sepsis patients had a confirmed sepsis diag-
nosis, which could be an explanation of the low mortality 
seen in this group. Patients were included with the diagno-
sis suspected sepsis based on SIRS or qSOFA scores in the 
medical files. We did not evaluate if the diagnosis sepsis of 
these patients was confirmed with microbiological data or 
otherwise because this study concerned the prediction of the 
identification of MALA patients in patients with suspected 
sepsis induced lactic acidosis in the ED.
We selected lactate and creatinine as potential relevant 
parameters to identify MALA patients in patients with sus-
pected sepsis induced lactic acidosis in the ED. CRP was 
significantly lower in the MALA patients but adding CRP 
did not improve the predictive value (data not shown). We 
chose not to select pH as a relevant parameter because pH is 
also dependent of carbon dioxide.
A sensitivity of 85% is not optimal and a higher sensitiv-
ity is desirable. In this study, 2 out of 13 MALA patients 
are not identified using this approach. Both patients had a 
lactate concentration exceeding 8.4 mmol/l but their cre-
atinine concentration was less than 256 μmol/l. MALA is 
often preceded by gastrointestinal symptoms e.g. nausea, 
vomiting and diarrhoea prior to admittance [4, 5, 7, 26]. The 
gastrointestinal problems lead to acute renal failure which 
subsequently leads to metformin accumulation causing lactic 
acidosis. Possibly, by taking gastrointestinal symptoms prior 
to admission into account, sensitivity could be improved.
The specificity of the combined parameters lactate and 
creatinine concentration is 95%. In Fig. 1 is shown that 
four sepsis patients have a lactate ≥ 8.4 mmol/l and a cre-
atinine ≥ 256 μmol/l and are therefore falsely identified as 
MALA patients using these two parameters. These patients 
did not use metformin and the specificity can be increased 
to 99% by adding metformin use as clinical parameter. How-
ever, metformin use may not always be directly available at 
the ED.
A strength of this study is that we defined MALA based 
on simultaneously measurement of lactate, pH and met-
formin serum concentration at admission. Lalau et al. [3] 
identified the lack of these combined data as one of the 
methodological flaws in most studies about MALA. Another 
strength is our selection of MALA patients. To minimize 
the discussion if metformin or comorbidity is causing lactic 
acidosis in patients using metformin we added the criterion 
metformin serum concentration > 5 mg/l to the generally 
accepted criteria of MALA pH < 7.35 and lactate > 5 mmol/l 
as suggested by Lalau et al. [3].
A limitation of the study is that comorbidity was not 
extracted separately from the medical records because this 
was diverse in the study population and difficult to quantify 
and to extract form the electronic patient files. However, 
we did extract the APACHE II scores, which is a common 
ICU scoring system for classifying disease state and pre-
dicting mortality and prognosis. There was no significant 
difference in APACHE II scores between the MALA and 
the suspected sepsis induced lactic acidosis group, reflecting 
comparable disease states and mortality risks. Another limi-
tation of our study regards to the retrospective single centre 
study design. In addition, the number of MALA patients 
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(N = 13) was very low which makes drawing conclusions 
on clinical implications from this study difficult. Because 
of the relatively low patient number, it was also not pos-
sible to perform multivariate regression analysis, which is 
the method of first choice in prediction research, so we had 
to calculate the sensitivity and specificity of the selected 
parameters manually. With multivariate regression analy-
sis, it is possible to estimate statistically significant rela-
tions between multiple independent clinical variables and 
outcome simultaneously. This would have made the results 
more accurate and robust. Furthermore, selection bias can-
not be excluded in our study. We selected patients based on 
lactate concentrations > 4.0 mmol/l. There is no hard crite-
rion defined for the lactate concentration to identify sepsis 
or septic shock. However, lactate levels exceeding 4 mmol/l 
correlate highly with underlying pathology and increased 
morbidity [22, 23, 31]. Therefore we selected patients with 
lactate > 4.0 mmol/l. However, patients with suspected sep-
sis and lactate < 4.0 mmol/l could have been missed. This 
also counts for MALA patients with no measured metformin 
concentrations. Finally, we divided the patients into two 
groups, i.e. MALA and suspected sepsis induced lactic aci-
dosis based on the inclusion and exclusion criteria. However, 
possibly, there were combined diagnoses and other comor-
bidity contributing to hyperlactatemia. 26% of the sepsis 
group used metformin but did not comply with the definition 
of MALA. Four patients in the MALA group had positive 
urine cultures but none of them had positive blood cultures.
Our findings are of important clinical relevance because 
of the high mortality of MALA and the necessity of start-
ing the right treatment immediately. The number of diabetes 
mellitus type 2 patients will increase the coming years and 
so is the use of metformin, thereby probably increasing the 
incidence of MALA [5]. Clinical symptoms of MALA and 
sepsis are similar and metformin serum concentration meas-
urement is not routinely available in most hospitals. In addi-
tion, sepsis confirmation by microbiologically testing takes 
days. In the treatment of MALA, ECTR is often necessary 
to remove metformin, clear lactate and correct acid–base 
abnormalities [19]. Therefore, a simple diagnostic approach 
identifying MALA patients in patients with suspected sep-
sis induced lactic acidosis in the ED is of high clinical rel-
evance. Lactate and creatinine are standard laboratory tests 
which are performed immediately at the ED when sepsis is 
suspected [8, 14, 22, 23, 31]. This study presents specific 
readily available clinical parameters in order to identify 
MALA patients, which gives direction in starting fast the 
right treatment, possibly leading to a better outcome. How-
ever, further research is necessary to improve the sensitivity 
of this approach and to validate the distinctive value in a 
prospective, multicentre design.
For clinical practice, we recommend that clinicians be 
alert to MALA in the ED when patients are admitted with 
severe lactic acidosis and renal failure. Knowledge of the 
metformin serum concentrations may be a valuable addi-
tional parameter for the diagnosis and management of 
MALA, despite the uncertainty concerning the prognostic 
value and the lack of a specific threshold for metformin to 
initiate ECTR [16–18]. Therefore, we recommend clinical 
pharmacists to organise access to a 24 h available metformin 
assay for hospitals treating MALA patients. Also, pharma-
cists can play an important role in preventing MALA by per-
forming adequate medication surveillance in patients using 
metformin and having renal failure and educating patients 
to temporarily stop metformin when they have symptoms of 
diarrhoea and vomiting [4, 26].
Conclusion
In case of lactic acidosis in the ED, besides sepsis, the diag-
nosis MALA should be considered in patients with a cre-
atinine concentration ≥ 256 μmol/l and lactate concentra-
tion ≥ 8.4 mmol/l. The sensitivity and specificity of these 
parameters combined with metformin use to identify MALA 
patients in patients with suspected sepsis induced lactic aci-
dosis were 85% and 99% respectively. As early recognition of 
MALA is essential for initiating the appropriate treatment in 
order to reduce morbidity and mortality and to avoid expen-
sive and high risk diagnostic tests, these parameters should be 
considered in managing lactic acidosis in the ED. A prospec-
tive, multicentre design validating the distinctiveness of these 
set of parameters is recommended to confirm these results.
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